RxDoctor Payments Data

Brian Santini, MD

Internal Medicine · Camarillo, CANPI 1417995754

Payments from drug & device makers

$421in general payments, 2019–2025

Across 23 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$94
  • Teva Pharmaceuticals USA, Inc.$61
  • Gilead$52
  • AstraZeneca$42
  • Cranial Technologies, Inc$37
  • Merck$37
  • plus $98 from 6 others

What the payments were for

  • Food & beverage$421100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$421 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$58,012
Medicare patients
205
Services billed
760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate87$104,492
JardianceEmpagliflozin61$64,092
EliquisApixaban44$54,994
XareltoRivaroxaban24$35,960
TradjentaLinagliptin15$19,271
FarxigaDapagliflozin Propanediol13$19,231
OzempicSemaglutide16$18,126
Repatha SureclickEvolocumab12$8,710
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,673
Incruse ElliptaUmeclidinium Bromide13$4,865
Losartan Potassium388$2,794
Atorvastatin Calcium418$2,766
Omeprazole216$2,659
Albuterol Sulfate HfaAlbuterol Sulfate105$2,448
Amlodipine Besylate450$2,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$37$104,49287 claims
Johnson & JohnsonXarelto$12$35,96024 claims
AstraZenecaFarxiga$42$19,23113 claims
Novo NordiskOzempic$13$18,12616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Camarillo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →